Cancer risks in thyroid cancer patients. by Hall, P. et al.
Br. J. Cancer (1991), 64, 159 163 © Macmillan Press Ltd., 1991
Cancer risks in thyroid cancer patients
P. Hall', L.-E. Holm2, G. Lundell', G. Bjelkengren3, L.-G. Larsson4, S. Lindberg5, J. Tennvall6,
H. Wicklund7 & J.D. Boice Jr8
'Department ofGeneral Oncology and 2Department ofCancer Prevention, Radiumhemmet, Karolinska Hospital, S-104 01
Stockholm; 3Department ofGeneral Oncology, Malmo General Hospital, S-214 01 Matmo; 4Oncology Center, University
Hospital, S-901 85 Ume&; 5Nuclear Medicine Section, Department ofGeneral Oncology, Sahtgren's Hospital, S-413 45
Gothenburg; 6Department ofGeneral Oncology, University Hospital, S-221 85 Lund; 7Department ofGeneral Oncology,
University Hospital, S-750 14 Uppsala, Sweden; 8Epidemiology and Biostatistics Program, Division ofCancer Etiology,
National Cancer Institute, Bethesda, Maryland 20892, USA.
Summary Cancer risks were studied in 834 thyroid cancer patients given 'l'I (4,551 MBq, average) and in
1,121 patients treated by other means in Sweden between 1950 and 1975. Record-linkage with the Swedish
Cancer Register identified 99 new cancers more than 2 years after 1311 therapy [standardised incidence ratio
(SIR)= 1.43; 95% confidence interval (CI) 1.17-1.75] vs 122 (SIR= 1.19; 95% CI 0.88-1.42) in patients not
receiving '3'I. In females treated with "'1I overall SIR was 1.45 (95% CI 1.14-1.83) and significantly elevated
were noted for tumours of the salivary glands, genital organs, kidney and adrenal gland. No elevated risk of a
subsequent breast cancer or leukaemia was noted. SIR did not change over time, arguing against a strong
radiation effect of '3'I. Organs that were estimated to have received more than 1.0 Gy had together a
significantly increased risk of a subsequent cancer following 131I treatment (SIR = 2.59; n = 18). A significant
trend was seen for increasing activities of 'I'I with highest risk for patients exposed to >3,664 MBq
(SIR = 1.80; 95% CI1.20-2.58). No specific cancer or group of cancers could be convincingly linked to
high-dose '"'I exposures since SIR did not increase after 10 years of observation. However, upper confidence
intervals could not exclude levels of risk that would be predicted based on data from the study of atomic
bomb survivors. We conclude that the current practice of extrapolating the effects of high-dose exposures to
lower-dose situations is unlikely to seriously underestimate radiation hazards for low LET radiation.
Iodine-131 was first described in medical practice more than
40 years ago and is still frequently used in the diagnosis and
treatment of thyroid disorders (Hamilton & Lawrence, 1942;
Hertz & Roberts, 1942).
In cases of nuclear explosions or reactor accidents large
amounts of 131I could be spread over vast areas causing a
potential hazard to human beings (Becker, 1987). Data on
risks associated with radioactive iodines are still relatively
scarce despite studies of populations exposed to fallout from
nuclear weapons testing (Conard, 1984; Hamilton et al.,
1987) and patients receiving diagnostic (Holm et al., 1989)
and therapeutic doses of '"'I (Brincker et al., 1973; Edmonds
& Smith, 1986; Hoffman, 1984; Holm, 1984; Saenger et al.,
1968).
Studies of thyroid cancer patients treated with '3'I are also
rare, probably because of the low incidence of the disease
and the associated small number of patients admitted to each
centre. High-dose '"'I has been linked to leukaemia following
treatment for thyroid cancer (Brincker et al., 1973; Edmonds
& Smith, 1986) and also to cancers of the bladder (Edmonds
& Smith, 1986). Record-linkage studies of patients with
thyroid cancer have reported increased risks of leukaemia
(Teppo et al., 1985), cancer of the breast, kidney and connec-
tive tissue (Tucker et al., 1985), and cancer of the nervous
tissue and non-Hodgkin's lymphoma (0sterlind et al., 1985).
The present study was designed to evaluate the risk of
second primary cancer in a cohort of thyroid cancer patients
treated with 13'I, and to contrast the risk with that of non-
exposed thyroid cancer patients.
Subjects and methods
Patient data were obtained from the oncologic centres of six
university hospitals in Sweden: (1) Lund; (2) Malm6; (3)
Gothenburg; (4) Stockholm; (5) Uppsala, and (6) UmeA. The
proportions of patients contributing to the study population
from each centre were 17%, 3%, 17%, 42%, 7%, and 14%,
respectively.
Between 1950 and 1975 a total of 2,510 patients under the
age of 76 years were admitted becuase of thyroid cancer.
Patients who died within 2 years after thyroid cancer diag-
nosis (n = 555) were excluded. Of these, 500 patients died
from thyroid cancer and 12 from other tumours, three of
which were diagnosed after the diagnosis of the thyroid
cancer. These were two cancers of the digestive tract and one
lung cancer.
The patients were divided into two groups according to 131I
therapy. Group I comprised 834 patients (74% females and
26% males) receiving '31I therapy and Group II, 1,121
patients (76% females and 24% males) not given such a
therapy. The mean age at the time of the thyroid cancer
diagnosis was 50 years (range 9-75 years) in Group I and 46
years (range 5-75 years) in Group II.
Thirty-two per cent of the patients in Group I had a
previous history of goitre vs 26% in Group II. The propor-
tions of patients, 4% in Group I vs 3% in Group II, with
previous external radiotherapy or 13'I therapy did not differ.
There was a higher proportion of previous surgical treatment
in Group I, 12% vs 5% in Group II.
A total thyroidectomy was performed as part of the
thyroid cancer treatment in 39% and a subtotal thyroid-
ectomy in 54% of the patients in Group I vs 45% and 48%
in Group II, respectively. The proportions of patients receiv-
ing chemotherapy did not differ, 6% vs 3% in Groups I and
II. External radiotherapy towards the neck region was given
to 36% and towards other parts of the body to 16% of the
patients in Group I. These figures were 37% and 6%, respec-
tively, in Group II.
Forty per cent of the females had a previous thyroid
disorder, compared to 28% in men. The proportion of
patients receiving treatment for the previous disorder was
15% and 11%, respectively.
There was no difference between the sexes regarding
thyroid cancer treatment (surgery, external radiotherapy,
chemotherapy), or in histopathological distribution of the
thyroid cancer.
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Tracer doses of '"'I were given postoperatively to most
patients after stimulation with thyroid stimulating hormones
and scintigraphic examinations were performed. The indica-
tion for "'I therapy depended on the amount and localisation
of any '3'I uptake, the surgical report, the tumour histo-
pathology, and the age of the patient. The principles for this
therapy varied between the centres.
Information on 24 h thyroid uptake of 131I was available in
61% of patients in Group I and the mean uptake was 21%
(range 1-57%) before the 131I treatment.
The mean total administered activity of '3'I was 4,551 MBq
(range 481-50,320 MBq, 37 MBq = 1 mCi). Seventy-eight
per cent of the patients were given "3'I to ablate thyroid
remnants (mean 3,145 MBq) and 22% because of distant
metastases (mean 9,916 MBq). Seventy-eight per cent of the
patients had one "31I treatment and 22% had two or more.
There was no difference in number of treatments between the
sexes.
Radiation doses to various organs were estimated assum-
ing a thyroid uptake of 25% and using the mean value of
4,551 MBq, ICRP tables (ICRP, 1988) and the data from
Smith and Edmonds (1983). The bladder and stomach
received on average 2.1 Gy, and the salivary glands and small
intestine 1.9 and 1.3 Gy, respectively. The pancreas, liver,
colon, lung, breast, ovary, uterus, testes, kidney, adrenal
gland, and bone marrow received 0.1-0.6Gy.
All patients who originally had been diagnosed as having a
thyroid cancer were included in the study. Papillary car-
cinoma of the thyroid was diagnosed in 54% of the patients
in Group I and in 62% in Group II. Follicular carcinoma
was more common in the 131I treated group, 31% vs 15%,
and poorly differentiated and medullary thyroid cancers were
less common in the '1'I treated group. The term 'poorly
differentiated' included diagnoses such as 'giant cell car-
cinoma', and 'anaplastic cancer'. Insufficient information on
histopathology was found in 5% and 7% in Group I and
Group II, respectively.
The total cohort was matched with the Swedish Cancer
Register (SCR) for reports on malignant tumours or
leukaemias occurring between 1958 and 1984. The SCR was
started in 1958 and collects nationwide data and receives
notifications on newly diagnosed cancers, not only from
clinicians but also from pathologists and cytologists. Most
diagnosed cases are thus reported by at least two indepen-
dent sources. More than 96% of all cancers in Sweden are
reported to the SCR (Mattsson & Wallgren, 1984). Patients
were matched using their unique 10-digit identification
number, which is given to each Swedish resident.
All patients were considered to be at risk from 2 years
after the time of initial 1311 treatment (Group I), thyroid
cancer diagnosis (Group II), or from 1958 if treated or
diagnosed prior to that year, and until death or December
Table I Observed no. of second
31, 1984. The median difference between date of diagnosis
and date of 131I therapy in Group I was 1 month.
All cancers observed during the first 2 years after initial
treatment/diagnosis, cancers reported prior to the diagnosis
of thyroid cancer (n = 66) and carcinoma in situ were ex-
cluded. The first 2 years at risk were also excluded in the
calculation of person-years. The expected numbers of malig-
nant tumours were calculated by indirect standardisation
with adjustment for calendar year, sex and age by applying
specific incidence data for the whole country obtained from
the SCR between 1958 and 1984.
The standardised incidence ratio (SIR) was calculated as
the ratio between observed and expected numbers of cancers.
The 95% confidence interval (CI) was determined by assum-
ing the observed number of cases to be distributed as a
Poisson variable. In some instances the ratio of SIRs of
exposed and non-exposed patients was assumed to be a
relative risk (RR).
Results
The person-years at risk in Group I were 10,073 and the
mean observation period was 14 years vs 15,757 person-years
and 16 years in Group II. Forty-one per cent of the patients
in Group I died and autopsy was performed in 16% of them
as compared to 33% and 10%, respectively, in Group II.
The mean period between the thyroid cancer and the
second cancer was 11 years in Group I (range 2-31 years)
and 12 years in Group II (range 2-32 years). Seven second
primary cancers were found at autopsy and each group.
In Group I, 99 second primary cancers were observed
(SIR= 1.43; 95% CI 1.17-1.75; Table I). Significantly
elevated SIRs were seen for salivary glands (SIR = 15.00;
n = 3), kidney (SIR = 3.00; n = 7), female genital organs
(SIR = 2.03; n = 18) and adrenal gland (SIR = 28.73; n = 2).
In Group II, 122 second primary cancers occurred
(SIR = 1.19; 95% CI 0.98-1.42; Table I). Cancer in adrenal
glands was above expectations (SIR = 41.76, n = 5). The risk
of leukaemia was above expectation in both groups, though
not significantly elevated.
In females, 168 second primary cancers were observed
(SIR= 1.29; 95% CI 1.10-1.50). SIR was 1.45 (95%
CI 1.14-1.83) for females receiving '"'I therapy, with
significantly elevated risks for salivary glands (SIR = 14.29;
n = 2), stomach (SIR = 2.85; n = 7), female genital organs
(SIR = 1.95; n = 18), kidney (SIR = 3.23; n = 5), and adrenal
gland (SIR = 28.57; n = 2). Overall cancer risk among
females in Group II was 1.18 (95% CI 0.96-1.45), with a
significantly elevated risk for adrenal gland (SIR = 18.18;
n = 2).
Among men, overall cancer risks did not differ from unity
primary cancers, SIR, and 95% CI in 1,955 thyroid
cancer patients
Group I Group II
Cancer site Obs. SIR 95% CI Obs. SIR 95% CI
Digestive tract 24 1.23 0.79- 1.84 35 1.17 0.84- 1.67
Salivary glands 3 15.00 3.09- 43.84 0 0.00 0.00-12.72
Stomach 7 1.75 0.71- 3.61 6 0.99 0.36- 2.15
Respiratory organs 5 1.11 0.36- 2.60 6 1.02 0.37- 2.21
Breast 9 0.74 0.34- 1.40 27 1.37 0.91- 2.00
Female genital organs 18 2.03 1.20- 3.20 11 0.77 0.38- 1.38
Male genital organs 4 0.85 0.23- 2.18 6 1.11 0.41- 2.41
Kidney 7 3.00 1.21- 6.19 5 1.48 0.48- 3.45
Bladder 4 1.61 0.44- 4.13 3 0.89 0.18- 2.61
Nervous system 5 2.43 0.79- 5.66 5 1.60 0.52- 3.73
Endocrine glands 6 5.13 1.88- 11.16 6 3.45 1.27- 7.51
Adrenal glands 2 28.73 3.46-103.21 5 41.76 13.53-97.23
Lymphomas 1 0.55 0.01- 3.06 3 1.10 0.23- 3.21
Leukaemias 4 2.44 0.66- 6.25 4 1.63 0.44- 4.16
All sites and cancer typesa 99 1.43 1.17- 1.75 122 1.19 0.98- 1.42
Person-years at risk 10,073 15,757
aIncludes sites and cancer types not listed in the table.CANCER RISKS IN THYROID CANCER PATIENTS 161
in any of the two treatment groups. A significantly elevated
risk was observed only for adrenal gland (SIR = 100.00;
n = 3) for males in Group II.
When cancer risk was related to age (0-35, 36-45, 46-55,
56-65 and 66-75 years) a significantly elevated risk was
found in the age group 36-45 years (SIR = 1.75; n = 19) in
Group I. No significantly elevated SIRs was seen in Group
II. There was no evidence of any pattern of risk by age at
treatment when contrasting the exposed and non-exposed
patients.
After 10 years or more of follow-up elevated risks were
seen in Group I for endocrine tumours other than thyroid,
and the overall risk was 1.44 (95% CI 1.05-1.92; Table II).
No signficiantly elevated overall risk was noted in Group II
(SIR = 1.20; 95% CI 0.93-1.51) although increased risk of
breast cancer was significantly above expectation (n = 19).
Cancer risks in the bladder, stomach, salivary glands, and
small intestine which all received > 1.0 Gy were above expec-
tation in Group I (SIR = 2.59; Table III), but not in Group
II (SIR = 0.95). Organs considered to receive 0.1-0.6 Gy, did
not show a significantly elevated risk in any of the treatment
groups. In organs receiving <0.1 Gy, SIR was significantly
elevated in Group I (SIR= 1.57).
When patients treated to ablate thyroid remnants were
studied separately among those receiving < 1,850 MBq
(mean 1,528 MBq; Table IV) no significantly elevated overall
risk was observed. Among patients receiving 1,851-3,663 MBq
(mean 2,639 MBq) a significantly elevated overall risk was
found (SIR= 1.54). In this group, SIR for cancer of the
female genital organs (SIR = 2.74; n = 8) was above expecta-
tion. Among patients given >3,664 MBq (mean activity
5,344 MBq), SIR was 1.80 (95% CI 1.20-2.58) and
significantly elevated SIRs were seen for salivary gland
(SIR = 40.00; n = 2), female genital organs (SIR = 2.82;
n = 6), and adrenal gland (SIR = 100.00; n = 2). In a weight-
ed regression analysis of the overall SIRs the trend was
statistically significant (P <0.05).
In Group I a higher overall risk was seen among those also
receiving external radiotherapy (SIR = 1.59; 95% CI
1.15-8.13) compared to those not given such therapy
(SIR = 1.24; 95% CI 0.93-1.61). This was in contrast to
Group II where the highest risk was seen among those not
given external radiotherapy, SIR = 1.33 (95% CI 1.03-1.69)
vs SIR= 1.04 (95% CI 0.78-1.35) for patients given this
treatment.
Discussion
Use of 131I in the treatment of thyroid cancer was not con-
vincingly linked to increases in leukaemia or cancer since we
were unable to detect a change in SIRs over time. The
overall cancer risk among '3'I exposed patients was 1.43
(95% CI 1.07-1.87) for the first 10 years, and did not change
during the following years. The same pattern was seen for
organs considered to receive quite high doses from "3'I
(>1 Gy; salivary gland, stomach, small intestine, bladder).
This is in contrast to findings among atomic bomb survivors
(Shimizu et al., 1990) were elevated risks for solid tumours
were reported after 10 years of observation. The short
follow-up could be one explanation. Other reasons could be
the relatively small number of patients studied and the
relatively low doses to most organs. For example, a RR of
1.51 (95% CI 0.20-11.21) was estimated for leukaemia and
based on the ratio of SIRs among exposed to non-exposed
patients. Assuming an average dose to the bone marrow of
0.3 Gy and applying the most recent estimate of risk from
the study of atomic bomb survivors of a 5.2% increase in the
RR of leukaemia per 0.01 Gy (Shimizu et al., 1990), the
expected radiogenic risk in our series would be RR = 2.6.
Although the possibility for this level of risk cannot be
excluded since it is within the 95% CI of the observed risk, it
does suggest that current estimates of radiogenic-induced
leukaemia based on high-dose data are unlikely to under-
estimate risks at low-dose levels. For solid tumours the RR
was 1.21 and the predicted value 1.2 based on the atomic
bomb data estimates of a 0.41% increase per 0.01 Gy
(Shimizu et al., 1990) and assuming that the average whole-
body dose for patients treated with '"'I in our study was
0.5 Gy (ICRP, 1988).
Other studies of thyroid cancer patients have reported
significant risks of leukaemia (Brincker et al., 1973; Edmonds
Table II Observed no. of second primary tumours, SIR, and 95% CI in thyroid cancer
patients followed 10 years or more
Group I Group II
Cancer site Obs. SIR 95% CI Obs. SIR 95% CI
Digestive tract 11 1.18 0.59- 2.11 22 1.31 0.83- 2.00
Salivary glands 0 0.00 0.00- 46.11 0 0.00 0.00-23.06
Stomach 2 1.14 0.14- 4.10 4 1.25 0.34- 3.19
Respiratory organs 1 0.48 0.01- 2.67 2 0.60 0.07- 2.16
Breast 5 0.90 0.29- 2.11 19 1.75 1.06- 2.74
Female genital organs 8 2.19 0.94- 4.31 5 0.69 0.22- 1.61
Male genital organs 2 0.89 0.11- 3.21 3 0.96 0.20- 2.80
Kidney 3 2.78 0.57- 8.12 2 1.05 0.13- 3.80
Bladder 1 0.85 0.02- 4.72 0 - 0.00- 1.91
Nervous system 3 3.33 0.69- 9.74 1 0.60 0.02- 3.36
Endocrine glands 3 5.45 1.12- 15.94 2 1.94 0.24- 7.01
Adrenal glands 1 33.33 0.84-185.72 1 16.67 0.42-92.86
Lymphomas 1 1.16 0.03- 6.48 2 1.28 0.16- 4.63
Leukaemias 2 2.78 0.34- 10.03 2 1.49 0.18- 5.39
All sites and cancer typesa 46 1.44 1.05- 1.92 69 1.20 0.93- 1.51
Person-years at risk 4,555 7,952
aIncludes sites and cancer types not listed in the table.
Table III Observed no. of second primary cancers, SIR, and 95% CI in organs grouped
according to estimated radiation dose
Radiation Group I Group II
dose to organs Obs. SIR 95% CI Obs. SIR 95% CI
High, > 1 Gy 18 2.59 1.53-4.09 10 0.95 0.45-1.73
Moderate, 0.1-0.6Gy 49 1.18 0.87-1.56 78 1.21 0.96-1.51
Low, <0.1 Gy 32 1.57 1.07-2.21 34 0.97 0.67-1.35162 P. HALL et al.
Table IV Observed no. of second primary cancers, SIR, and
95% CI in relation to amount of administered '"'I
Amount of Person-
administered 13'I, years Observed
Mbq at risk no. SIR 95% CI
0 15,757 123 1.20 0.99-1.43
< 1,850 2,655 22 1.31 0.82-1.98
1,851-3,663 2,998 33 1.54 1.06-2.16
3,664 2,363 29 1.80 1.20-2.58
& Smith, 1986). Patients treated with lower doses of '31I for
hyperthyroidism (200-900 MBq) have not been found to be
at increased risk for leukaemia (Hoffman, 1984; Holm, 1984).
One survey suggests that patients with thyroid disorders
might have a predisposition for developing leukaemia
(Saenger et al., 1968).
Women with thyroid cancer had a higher risk than men of
developing a second primary cancer. There was no marked
difference between the sexes in the treatment of the thyroid
cancer, age distribution, patients treated for distant meta-
stases or cases diagnosed at autopsy. The latest findings from
the A-bomb survivors did not indicate a difference between
the sexes in cancer mortality, except for leukaemia where
men had a higher risk (Shimizu et al., 1990).
A statistically significant excess was observed for the
salivary glands. This finding was based on three cases, one of
whom also received external irradiation to the neck region.
Salivary gland cancer has not previously been observed after
13'I therapy, but has been reported following relatively high-
dose external irradiation (Maxon et al., 1981).
An increased risk for tumours of the adrenal gland was
noted in both treatment groups, and suggests the possibility
of an underlying predisposition or common etiological fac-
tors. In 1961, Sipple noted the coexistence of medullary
thyroid carcinoma, pheocromocytoma and later parathyroid
adenoma. Seven of the 12 endocrine tumours in this study
were pheocromocytomas and three parathyroid tumours.
Five patients with pheocromocytoma had a previous history
of medullary thyroid carcinoma. The knowledge among
physicians to search for other endocrine tumours in thyroid
cancer patients could contribute to our findings.
The risk was significantly elevated for a subsequent kidney
cancer (SIR = 3.00; n = 7) but not for bladder cancer
(SIR = 1.61; n = 4) in Group I. This is noteworthy since the
dose to the bladder was calculated to be eight times higher
than for the kidney. One explanation could be the screening
for pheocromocytoma. Significantly elevated risks for bladder
cancer (Edmonds & Smith, 1986) and kidney cancer (Tucker
et al., 1985) have previously been described.
The absence of a breast cancer excess in the "'lI treated
group is noteworthy since previous studies have suggested a
link with "'lI therapy (Goldman et al., 1988; Teppo et al.,
1985), or a common etiology for breast and thyroid cancer
(Ron et al., 1984). A significant excess of breast cancer was
found among patients not given "'lI who survived > 10 years.
The elevated risk among patients receiving higher activity
of 13I1 suggests a dose-response relationship but could be
somewhat misleading since radiation doses are dependent of
the thyroid 24-h uptake. Further calculations on individual
organ- and whole-body doses are needed.
The close medical surveillance of cancer patients may have
contributed to the detection of some cancers that would not
otherwise have led to the clinically apparent disease, resulting
in artefactually increased risks in both groups. No difference
in the proportion of second primary cancers found at
autopsy was observed in the two groups, although the
autopsy rate was higher in the 'llI treated group.
External radiotherapy did not seem to have a major
impact on cancer risks since the overall risk was higher in
patients not receiving external radiotherapy (SIR= 1.29;
95% CI 1.07-1.54) than in patients receiving this treatment
(SIR = 1.23; 95% CI 1.00-1.49). There was no difference in
the percentage ofpatients in Groups I and II having received
external radiotherapy, although the "'lI treated group were
irradiated outside the neck region more often, 16% vs 6%.
The observed second primary cancers were all found in
thyroid cancer patients treated at university hospitals in
major cities and expected values were calculated from the
Swedish population as a whole, which thus would result in
an overestimate of the SIRs.
When interpreting our results several methodologic strengths
and weaknesses should be considered. The strengths include
the detailed information on administered "3'I activity which
facilitates organ dose estimation, the availability of a non-
exposed comparison group, and the accurate and complete
ascertainment of subsequent malignancies through linkage
with the national cancer register. Weaknesses include the
relatively small number of patients studied, the possibility
that selection biases might exist with regard to treatment, the
roles that increased surveillance or misdiagnosed metastases
might play, the use of average organ doses and not individ-
ual estimates.
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